article thumbnail

Astellas Pharma CEO Q&a (Part 2): We Have To Have Alternatives for Prescription Medicine Business

MedCity News

In part 2 of our Q&A, Okamura addresses the need for biopharma companies to leverage digital technologies in disease management. The post Astellas Pharma CEO Q&a (Part 2): We Have To Have Alternatives for Prescription Medicine Business appeared first on MedCity News.

article thumbnail

AI-Enabled Prescription Digital Therapeutics Should Be An Investment Priority

MedCity News

Some companies are doing just that via Software as a Medical Device (SaMD), particularly by developing prescription digital therapeutics (PDTs). To identify true growth opportunities, investors must consider how companies are using AI to revolutionize the treatment journey.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Why Blue Shield of California Is Shaking Up its Prescription Drug Model

MedCity News

Blue Shield of California is cutting many of its ties with CVS Caremark (though not all) and adding four additional partners for its prescription drug benefits. These partners include Mark Cuban Cost Plus Drug Company and Amazon Pharmacy.

article thumbnail

Ipsen beefs up in oncology, buying US biopharma Epizyme

pharmaphorum

The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescription pharma operating in the cancer, rare diseases and neuroscience categories. The post Ipsen beefs up in oncology, buying US biopharma Epizyme appeared first on.

Biopharma 110
article thumbnail

Access solutions: the missing link that prevents biopharma innovation from reaching patients

pharmaphorum

The clerical overhead of enrolment forms navigated over fax and phone calls fails to deliver on the promise, resulting in lower-than-expected prescription volumes and lacklustre adoption among prescribers. The post Access solutions: the missing link that prevents biopharma innovation from reaching patients appeared first on.

article thumbnail

Navigating the Challenges of Biopharma Product Launches: A Blueprint for Success

PM360

Embarking on the journey from product development to market success in the biopharma industry is no small feat. The landscape is highly competitive with new prescription medications launching worldwide each year. However, this journey is fraught with challenges as revealed by an in-depth analysis.

article thumbnail

In midterm speeches, President Biden focuses on Rx drug costs to cut inflation

MedCity News

President Biden continues to center his pre-midterm speeches around the issue of prescription drug costs, […].